Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | HERO: relugolix as an oral androgen-deprivation therapy in prostate cancer

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Louvain, Belgium, discusses findings from the Phase III HERO study (NCT03085095), which evaluated relugolix, an gonadotropin-releasing hormone antagonist, against leuprolide in men with advanced prostate cancer. Relugolix is the first oral androgen-deprivation therapy and resulted in fewer cardiac events in patients with a previous cardiac history. The novel hormone antagonist additionally resulted in a higher proportion of patients with profound castrate levels, defines as a testosterone level of less than 20ng/dL. This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. Tombal reports the conflicts of interest:
Advisor and/or investigator for AstraZeneca, MSD, Pfizer, Astellas